CClinicalTrials.gg
CompletedNCT06578832Updated Aug 29, 2024

Assessment of The Oral Health Status of Children With Chronic Kidney Disease

An observational study in Chronic Kidney Diseases, Caries,Dental and Quality of Life, sponsored by Marmara University. Completed at 1 site in Turkey. Open to participants aged 1 Year to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by Marmara University · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
167
Ages
1 Year to 18 Years
Sex
All
01

Study summary

The aim of this study is to compare the oral health findings, salivary parameters and disease-related quality of life of children with different stages of Chronic Kidney Disease(CKD), those undergoing dialysis and transplantation, with healthy children, and to evaluate certain serum biomarkers in children with CKD.

Read the detailed description

Chronic kidney disease (CKD) is a progressive and irreversible decline in the function of many nephrons and glomerular filtration rate due to kidney diseases. This decline leads to increased serum levels of urea and creatinine. Patients with CKD often exhibit various oral manifestations, such as an ammonia-like odor, gingival enlargement due to drug therapy, enamel hypoplasia, dental calculus, dry mouth, uremic stomatitis, and oral mucosal lesions. Interestingly, children with CKD tend to have a lower prevalence of dental caries, likely due to the high urea content in their saliva, which has antibacterial properties. CKD is also associated with salivary gland dysfunction and increased oxidative damage. Furthermore, CKD patients have reduced bone quality, making them more susceptible to fractures. A study on the quality of life (QoL) in children with CKD and their parents reported significantly lower physical and social QoL scores in children undergoing hemodialysis compared to healthy controls. This study aims to comparatively evaluate and analyze children diagnosed with different stages of chronic kidney disease (CKD) and healthy children without any systemic conditions, focusing on their age, gender, and oral health habits such as tooth brushing frequency, dental floss usage, and annual dentist visits. Disease-related information such as the stage of CKD, dialysis, and transplantation, as well as oral findings, will be examined using DMFT/dft, ICDAS II, DDE, BAKH, DI, CI, OHI-S, and MGI indices. The study will assess general disease-related quality of life from both the child's and the parent's perspectives using the KINDLR scale. Additionally, salivary samples collected from children with CKD and healthy children will be analyzed for salivary flow rate, pH, buffering capacity, total oxidant and antioxidant capacities, urea, calcium, potassium, and phosphorus levels. Serum urea, calcium, and phosphorus values will also be examined.

02

Conditions studied

  • Chronic Kidney Diseases
  • Caries,Dental
  • Quality of Life
  • Saliva Altered
  • Periodontitis

Keywords

  • Chronic kidney disease
  • oral health
  • salivary
  • quality of life
03

In context

Periodontitis

1,635 studies on the registry are indexed under Periodontitis; 327 are open to participants now.

This study's enrollment of 167 is above the median of 90 across 428 observational studies indexed under Periodontitis.

Browse Periodontitis studies →

Lead sponsor

Marmara University is the lead sponsor of 576 studies on the registry; 136 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Being followed up for a diagnosis of chronic kidney disease

Inclusion criteria

  • Not having any systemic disease.
  • Not being on any regular medication.

Exclusion criteria

Exclusion Criteria:

  • Having any systemic disease.
  • Being on any regular medication.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
167 participants (actual)
Target follow-up
6 Months
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Children with chronic kidney disease

    It is a group of patients between the ages of 4 and 17 who have recently been diagnosed with jchronic kidney disease

    Diagnostic Test: physical and chemical methods · Diagnostic Test: biochemical methods · Diagnostic Test: biochemical tests · Diagnostic Test: Oral Health Habits · Diagnostic Test: Oral Findings · Diagnostic Test: Quality of Life Assessment

  • Healthy patient group

    Healthy children aged between 4 and 17 years, with no systemic diseases and not taking any regular medications.

    Diagnostic Test: physical and chemical methods · Diagnostic Test: biochemical methods · Diagnostic Test: biochemical tests · Diagnostic Test: Oral Health Habits · Diagnostic Test: Oral Findings · Diagnostic Test: Quality of Life Assessment

  • Children with chronic kidney disease receiving dialysis treatment

    It is a group of patients aged between 4 and 17 who have recently been diagnosed with chronic kidney disease and are receiving dialysis treatment.

    Diagnostic Test: physical and chemical methods · Diagnostic Test: biochemical methods · Diagnostic Test: biochemical tests · Diagnostic Test: Oral Health Habits · Diagnostic Test: Oral Findings · Diagnostic Test: Quality of Life Assessment

  • Children with chronic kidney disease who have undergone a kidney transplant

    It is a group of patients aged between 4 and 17 who have recently been diagnosed with chronic kidney disease and have undergone a kidney transplant.

    Diagnostic Test: Oral Health Habits · Diagnostic Test: Oral Findings · Diagnostic Test: Quality of Life Assessment

  • Children with stage 1-3 chronic kidney disease

    It is a group of patients aged between 4 and 17 who have been diagnosed with stage 1-3 chronic kidney disease

    Diagnostic Test: physical and chemical methods · Diagnostic Test: biochemical methods · Diagnostic Test: biochemical tests · Diagnostic Test: Oral Health Habits · Diagnostic Test: Oral Findings · Diagnostic Test: Quality of Life Assessment

  • Children with stage 4-5 chronic kidney disease

    It is a group of patients aged between 4 and 17 who have been diagnosed with stage 4-5 chronic kidney disease

    Diagnostic Test: physical and chemical methods · Diagnostic Test: biochemical methods · Diagnostic Test: biochemical tests · Diagnostic Test: Oral Health Habits · Diagnostic Test: Oral Findings · Diagnostic Test: Quality of Life Assessment

Interventions

  • Diagnostic testphysical and chemical methods

    Salivary flow rate, pH, buffering capacity

  • Diagnostic testbiochemical methods

    Total oxidant and antioxidant capacities

  • Diagnostic testbiochemical tests

    urea, calcium, potassium, phosphorus

  • Diagnostic testOral Health Habits

    Tooth brushing frequency Dental floss usage Annual dentist visits

  • Diagnostic testOral Findings

    DMFT/dft Index: Measures decayed, missing, and filled teeth. ICDAS II: International Caries Detection and Assessment System, used for detecting and assessing dental caries. DDE Index: Developmental Defects of Enamel index. BAKH Index: Basic Anatomic Keratinization Hierarchy, typically used in specific studies. DI (Debris Index): Assesses oral hygiene based on the amount of debris on the teeth. CI (Calculus Index): Measures the amount of calculus (tartar) on the teeth. OHI-S (Simplified Oral Hygiene Index): Assesses oral hygiene based on the presence of debris and calculus. MGI (Modified Gingival Index): Assesses the severity of gingivitis based on inflammation.

  • Diagnostic testQuality of Life Assessment

    KINDLR Scale: Used to assess disease-related quality of life from both the child's and the parent's perspectives.

06

What researchers measure

Primary outcomes

  1. Oral Health Status

    DMFT/dft indices, DI (Debris Index), CI (Calculus Index), and OHI-S (Simplified Oral Hygiene Index) scores,DDE Index (Developmental Defect of Enamel), MGI Index (Modified Gingival Index) and ICDAS-II. DMFT/dft index values, DI, CI, and OHI-S scores as numerical values. DDE, MGI Index and ICDAS-II are percentage of participants with these conditions. Prevalence of limited opacities, caries and gingival inflammation based on DDE, ICDAS II and MGI indices.

    Time frame: baseline

  2. Salivary Analysis

    Salivary urea, calcium (Ca), potassium (K), phosphorus (P), total oxidant status (TOS) levels, and salivary flow rate. Concentration of urea, Ca, K, P, TOS in mg/dL or equivalent, and salivary flow rate in mL/min.

    Time frame: baseline

  3. Quality of Life (QoL)

    Quality of life scores on the KINDLR scale for both children with CKD and their parents

    Time frame: baseline

Secondary outcomes

  1. Correlation Between Oral Health Indices and Salivary Biomarkers

    Correlation between DMFT/dft index, DI, CI, OHI-S scores, and salivary levels of urea, calcium (Ca), potassium (K), phosphorus (P), total oxidant status (TOS), and total antioxidant status (TAS). Pearson or Spearman correlation coefficient. DMFT/dft index, DI, CI, OHI-S scores for oral health assessment; biochemical analysis for salivary biomarker levels.

    Time frame: baseline

  2. Correlation Between Salivary Urea and Serum Urea Levels

    Correlation between salivary urea levels and serum urea levels. Pearson or Spearman correlation coefficient. Biochemical analysis for salivary and serum urea levels.

    Time frame: baseline

  3. Correlation Between Salivary and Serum Calcium and Phosphorus Levels:

    Correlation between salivary calcium and phosphorus levels and serum calcium and phosphorus levels. Pearson or Spearman correlation coefficient. Biochemical analysis for salivary and serum calcium and phosphorus levels.

    Time frame: baseline

07

Study locations

1 site
  • Marmara University Faculty of Dentistry
    Istanbul, Maltepe, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06578832
Lead sponsor
Marmara University
Responsible party
Sponsor
First posted
Aug 29, 2024
Start date
Aug 10, 2022
Primary completion
Sep 6, 2023
Completion
Jan 18, 2024
Last update
Aug 29, 2024

Study contacts

Harika Alpay, Prof
study chair · Marmara University Faculty of Medicine
İbrahim Gökçe, Prof
study chair · Marmara University Faculty of Medicine
Nurdan Yıldız, Prof
study chair · Marmara University Faculty of Medicine
Nihal Şehkar Oktay, Assoc. Prof
study chair · Marmara University Faculty of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion